NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT06898957 2026-04-22
(DeLLphi-310)
Amgen
Phase 1 Active not recruiting
NCT04605731 2026-04-20
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07391670 2026-04-17
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07531095 2026-04-15
DeLLphi-313
Amgen
Phase 1 Not yet recruiting
NCT04686305 2026-04-13
DL03
AstraZeneca
Phase 1 Recruiting
NCT05411094 2026-04-13
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04612751 2026-04-06
TROPION-Lung04
AstraZeneca
Phase 1 Active not recruiting
NCT07107750 2026-04-03
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT02537418 2026-03-27
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Canadian Cancer Trials Group
Phase 1 Active not recruiting